TY - JOUR
T1 - Small cell lung cancer
T2 - Clinical practice guidelines in oncology
AU - Kalemkerian, Gregory P.
AU - Akerley, Wallace
AU - Bogner, Paul
AU - Borghaei, Hossein
AU - Chow, Laura QM
AU - Downey, Robert J.
AU - Gandhi, Leena
AU - Ganti, Apar Kishor P.
AU - Govindan, Ramaswamy
AU - Grecula, John C.
AU - Hayman, James
AU - Heist, Rebecca Suk
AU - Horn, Leora
AU - Jahan, Thierry
AU - Koczywas, Marianna
AU - Loo, Billy W.
AU - Merritt, Robert E.
AU - Moran, Cesar A.
AU - Niell, Harvey B.
AU - O'Malley, Janis
AU - Patel, Jyoti D.
AU - Ready, Neal
AU - Rudin, Charles M.
AU - Williams, Charles C.
AU - Gregory, Kristina
AU - Hughes, Miranda
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.
AB - Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.
KW - Antineoplastic Agents/therapeutic use
KW - Brain Neoplasms/prevention & control
KW - Humans
KW - Lung Neoplasms/pathology
KW - Neoplasm Staging
KW - Radiotherapy
KW - Small Cell Lung Carcinoma/secondary
UR - http://www.scopus.com/inward/record.url?scp=84874589027&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000313575200011&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2013.0011
DO - 10.6004/jnccn.2013.0011
M3 - Article
C2 - 23307984
SN - 1540-1405
VL - 11
SP - 78
EP - 98
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 1
ER -
